Seqens has more than 50 years of experience in developing and producing high-quality APIs.

TRUSTED SUPPLIER of APIS

With 1 000/m3 of cGMP production capacity, 130 R&D chemists and seven pilot units providing first class R&D capabilities, and proprietary technology, such as biocatalysis, to develop unique processes, Seqens has the capacity and competence to develop your API project successfully, to scale up production as needed, and to handle regulatory filings at every stage and in all markets.

Seqens has an in-house IP team for the design of non-infringing patent process to assure the customer the freedom to operate on the target market at the desired launch. But our target is not only to be the first but also to last to be part of the long term success of the project, that’s why in addition to patent-free we develop cost competitive products by incorporating original technologies and working on the last array of chemistries where Seqens has a strong knowhow.


We offer a dependable manufacturing network of five cGMP plants in Europe and one in the United States, all of which have a strong track record dealing with the Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) and the Pharmaceuticals, Medical Devices Agency (PMDA) in Japan and other international regulatory agencies.


More than 50 APIs have been successfully launched in the United States, Europe and Japan with consistently superior quality, reliability and customer service, and supported by regulatory documentation to meet the most stringent standards from local agencies.

In house back integration for starting materials

Additionally, to minimize the impact of variability in the quality of raw materials on production timelines and regulatory approval, Seqens’ has several pre-GMP sites that provide supply security with back-integration of raw material and regulatory starting materials. Without having to depend on third parties, we can obtain advanced intermediates in the necessary quantities for your project, while also controlling cost of critical materials. 

Multisite backup production of an API

Several GMP compliance production sites, Seqens can offer an additional level of supply security by offering the possibility of incorporating another site for the API production.

Our locations

Address Route de Lassay
61410 Couterne
Business Line Lubbricant Additives, Fine Chemicals
Phone +33 2 33 37 50 20
Market Specialty Ingredients
Mail info.AS@seqens.com
More information

Surface: 120, 000 m²

Capabilities: 190 m³ of ISO 9001 reactors and kilo-lab

Flagship technologies: Most standard organic synthesis reactions (large volumes)

Certifications: ISO 9001

Address Raiffeisenstraße 4
77933 Lahr
Business Line Custom Manufacturing, APIs & Intermediates
Phone 49 7821 585 0
Market Pharmaceutical
Mail info-lahr@seqens.com
More information

Surface: 48 000 m²

 

Lab surface: 700 m²

 

Capabilities:

  • Total reactor capacity: 92 m³
  • Reaction vessels: 1 to 6 300 L; temperature  -80°C to +250 °C
  • Multi-purpose state of the art cGMP facilty: 4 independent, vertical integrated production trains 800 L train, 2 x 3 000 L trains plus 1 x 3 000 L low temperature hydrogenation reactor and 6 000 L train
  • Classic two-floor layout Facility: 20 vessels with capacity between 800 and 6 000 L (glaslined and SS)
  • Autoclaves (operational range up to 100 bar)
  • Kilo-Lab: 3 reactors: 25 / 100 / 250 L

Flagship technologies:

  • Hydrogenation
  • Reductive amination
  • Organometallic reactions
  • Protected AADs (Aminoacid derivatives)
  • Carbonylation & Hydroformylation
  • Pressure aminolysis, other reactions under pressure
  • Cryogenic chemistry
  • Enantiopure synthesis
  • Cyanation high volumes (NaCN) C-C coupling
  • Reductions
  • Halogenation

Last inspections:

  • FDA 2018
  • German Pharma Authority 2018

Certifications:

  • GMP
  • ISO 9001
  • ISO 50001

Number of scientists: 25

 
Address 19 Route de Meulan
78520 Limay
Business Line Contract Manufacturing & Proprietary APIs
Phone +33 1 34 78 87 87
Market Pharmaceutical
Mail info.cdmo@seqens.com
More information

Capabilities: 

  • 70 m³ of GMP reactors
  • 100 L – 8 000 L vessels

Flagship technologies: 

  • Optical resolution
  • Enzymatic hydrolysis
  • Enantioselective reduction
  • Low-temperature reactions (-80 °C)
  • Specific reduction
  • Hydrogenation (40 bar)
  • Organomagnesium compounds
  • Thin-layer distillation
Address Expansia, Route d'Avignon
30390 Aramon
Business Line Contract Manufacturing
Phone +33 4 66 57 01 01
Market Pharmaceutical
Mail info.cdmo@seqens.com
More information

Capabilities: 

  • 100 m³ of GMP reactors
  • 50 L – 10 000 L vessels

Flagship technologies: 

  • Organometallic chemistry
  • Large-scale hydrogenation
  • Diborane chemistry
  • Ethylene oxide reactions
  • Biocatalysis platform
  • Polymer production (PLGA)
  • Enzymatic synthesis Skraup reactions
Address 15 Avenue des Frères Lumière
38300 Bourgoin-Jallieu
Business Line Contract Manufacturing & Fine Chemicals
Phone +33 4 74 93 63 33
Market Pharmaceutical
Mail Acceuil.bourgoin@seqens.com
More information

Flagship technologies: Distillation

Address 35 Avenue Jean Jaurès
92390 Villeneuve-la-Garenne
Business Line Contract Manufacturing & Proprietary APIs
Phone +33 1 34 78 87 87
Market Pharmaceutical
Mail info.cdmo@seqens.com
More information

Capabilities: 

  • 70 m³ of GMP reactors
  • 100 L – 8 000 L vessels

Flagship technologies: 

  • Optical resolution
  • Enzymatic hydrolysis
  • Enantioselective reduction
  • Low-temperature reactions (-80 °C)
  • Specific reduction
  • Hydrogenation (40 bar)
  • Organomagnesium compounds
  • Thin-layer distillation
Address Messukentänkatu 8
20210 Turku
Business Line Contract Manufacturing & Proprietary APIs
Phone +358 2 330 5542
Market Pharmaceutical
Mail info@pcasfinland.fi
More information

Surface: 11 678 m²

Lab surface: 695 m²

Capabilities: 

  • 4 separate modules
  • 72 m³ reactor capacity-
  • 250 L – 6300 L vessels

Flagship technologies:

  • Biphosphonate chemistry
  • Hydrogenation (20 bar)
  • Chlorination
  • Cyanation (NaCN) in separate installations
  • Reduction with complex hydrids
  • Biocatalysis
  • Manufacturing of parenteral/injectable APIs
  • Separate production modules and final processing facilities
 

Last inspections:

  • FDA 2017
  • PMDA 2018
  • FIMEA 2018

Number of scientists: 16

Address 9 Opportunity Way
MA 01950 Newburyport
Business Line Custom Early Phase Pharmaceutical
Phone (978) 462 5555
Market Pharmaceutical
Mail derek.richards@seqens.com
More information

Surface: 5, 600 m²

Lab surface: 460 m²

Capabilities:

  • Process Research – Custom synthesis & synthetic route evlaution from g – kg for API’s or intermediates
  • Process Development – Custom synthesis from kg – metric tons
  • cGMP Small Molecule API Manufacturing (Phase 1, Phase 2, Phase 3, Commerical)
  • cGMP Medical Grade Polymers, Analytical Method Development

Flagship technologies: 

  • Controlled Substances
  • Cryogenic Chemistry -90°C
  • Lyophilization, Small/Large Scale Chromatography
  • Tangential Flow Filtration

Last inspection: July 2018 FDA Inspection